177 related articles for article (PubMed ID: 20665103)
1. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
[TBL] [Abstract][Full Text] [Related]
2. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Jumppanen M; Gruvberger-Saal S; Kauraniemi P; Tanner M; Bendahl PO; Lundin M; Krogh M; Kataja P; Borg A; Fernö M; Isola J
Breast Cancer Res; 2007; 9(1):R16. PubMed ID: 17263897
[TBL] [Abstract][Full Text] [Related]
3. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
[TBL] [Abstract][Full Text] [Related]
4. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
Button B; Croessmann S; Chu D; Rosen DM; Zabransky DJ; Dalton WB; Cravero K; Kyker-Snowman K; Waters I; Karthikeyan S; Christenson ES; Donaldson J; Hunter T; Dennison L; Ramin C; May B; Roden R; Petry D; Armstrong DK; Visvanathan K; Park BH
Breast Cancer Res Treat; 2019 Apr; 174(2):401-412. PubMed ID: 30560461
[TBL] [Abstract][Full Text] [Related]
5. Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Munne PM; Martikainen L; Räty I; Bertula K; Nonappa ; Ruuska J; Ala-Hongisto H; Peura A; Hollmann B; Euro L; Yavuz K; Patrikainen L; Salmela M; Pokki J; Kivento M; Väänänen J; Suomi T; Nevalaita L; Mutka M; Kovanen P; Leidenius M; Meretoja T; Hukkinen K; Monni O; Pouwels J; Sahu B; Mattson J; Joensuu H; Heikkilä P; Elo LL; Metcalfe C; Junttila MR; Ikkala O; Klefström J
Nat Commun; 2021 Nov; 12(1):6967. PubMed ID: 34845227
[TBL] [Abstract][Full Text] [Related]
6. The value of oestrogen receptor, progesterone receptor and keratins 5 and 14 immunohistochemistry in the evaluation of epithelial proliferations at cauterised margins in breast-conserving surgery specimens.
Almási S; Cserni G
Pathol Res Pract; 2024 May; 257():155280. PubMed ID: 38608372
[TBL] [Abstract][Full Text] [Related]
7. Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers.
Truong TH; Lange CA
Endocrinology; 2018 Dec; 159(12):3897-3907. PubMed ID: 30307542
[TBL] [Abstract][Full Text] [Related]
8. Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer.
Harrell JC; Shroka TM; Jacobsen BM
Oncogenesis; 2017 Nov; 6(11):396. PubMed ID: 29176653
[TBL] [Abstract][Full Text] [Related]
9. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
[TBL] [Abstract][Full Text] [Related]
10. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
[TBL] [Abstract][Full Text] [Related]
11. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
[TBL] [Abstract][Full Text] [Related]
12. The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling.
Wei W; Liu W; Cassol CA; Zheng W; Asa SL; Ezzat S
Mol Cell Biol; 2012 Nov; 32(22):4662-73. PubMed ID: 22988296
[TBL] [Abstract][Full Text] [Related]
13. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
[TBL] [Abstract][Full Text] [Related]
14. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 5-Positive Cells Represent a Therapy Resistant subpopulation in Epithelial Ovarian Cancer.
Corr BR; Finlay-Schultz J; Rosen RB; Qamar L; Post MD; Behbakht K; Spillman MA; Sartorius CA
Int J Gynecol Cancer; 2015 Nov; 25(9):1565-73. PubMed ID: 26495758
[TBL] [Abstract][Full Text] [Related]
16. The late-annotated small ORF LSO1 is a target gene of the iron regulon of Saccharomyces cerevisiae.
An X; Zhang C; Sclafani RA; Seligman P; Huang M
Microbiologyopen; 2015 Dec; 4(6):941-51. PubMed ID: 26450372
[TBL] [Abstract][Full Text] [Related]
17. Multiple Hepatic Lesions in a Patient With a History of DCIS.
Jasem J; Altoos B; Fisher CM; Elias AD; Kounalakis N; Borges VF; Kabos P
Oncology (Williston Park); 2015 Sep; 29(9):669-70, 678-9. PubMed ID: 26384804
[No Abstract] [Full Text] [Related]
18. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
20. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
